- Home
- ELTK vs ARMP Comparison
ELTK vs ARMP Comparison
Compare ELTK & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELTK
- ARMP
- Stock Information
- Founded
- ELTK 1970
- ARMP N/A
- Country
- ELTK Israel
- ARMP United States
- Employees
- ELTK N/A
- ARMP N/A
- Industry
- ELTK Electrical Products
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELTK Technology
- ARMP Health Care
- Exchange
- ELTK Nasdaq
- ARMP Nasdaq
- Market Cap
- ELTK 57.5M
- ARMP 52.1M
- IPO Year
- ELTK 1997
- ARMP N/A
- Fundamental
- Price
- ELTK $8.53
- ARMP $1.23
- Analyst Decision
- ELTK
- ARMP Strong Buy
- Analyst Count
- ELTK 0
- ARMP 1
- Target Price
- ELTK N/A
- ARMP $7.00
- AVG Volume (30 Days)
- ELTK 8.1K
- ARMP 30.3K
- Earning Date
- ELTK 05-20-2025
- ARMP 05-06-2025
- Dividend Yield
- ELTK 2.23%
- ARMP N/A
- EPS Growth
- ELTK N/A
- ARMP N/A
- EPS
- ELTK 0.63
- ARMP N/A
- Revenue
- ELTK $46,527,000.00
- ARMP $5,174,000.00
- Revenue This Year
- ELTK $18.60
- ARMP $8.43
- Revenue Next Year
- ELTK $9.04
- ARMP N/A
- P/E Ratio
- ELTK $13.54
- ARMP N/A
- Revenue Growth
- ELTK N/A
- ARMP 14.24
- 52 Week Low
- ELTK $7.65
- ARMP $0.90
- 52 Week High
- ELTK $12.47
- ARMP $3.45
- Technical
- Relative Strength Index (RSI)
- ELTK 45.32
- ARMP 39.22
- Support Level
- ELTK $8.39
- ARMP $1.11
- Resistance Level
- ELTK $8.71
- ARMP $1.30
- Average True Range (ATR)
- ELTK 0.32
- ARMP 0.14
- MACD
- ELTK 0.14
- ARMP 0.01
- Stochastic Oscillator
- ELTK 83.02
- ARMP 42.86
About ELTK Eltek Ltd.
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnects. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.